MC
CLDX icon

Marcus Capital’s Celldex Therapeutics CLDX Stock Holding History

Marcus Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,920
Closed -$256K – 47
2017
Q2 		$256K Sell
6,920
-417
-6% -$18.4K 0.22% 49
2017
Q1 		$397K Buy
7,337
+7
+0.1% +$365 0.37% 46
2016
Q4 		$389K Sell
7,330
-150
-2% -$8.53K 0.42% 46
2016
Q3 		$453K Buy
7,480
+40
+0.5% +$2.49K 0.44% 46
2016
Q2 		$490K Buy
7,440
+2,747
+59% +$174K 0.52% 46
2016
Q1 		$266K Buy
4,693
+1,463
+45% +$165K 0.29% 48
2015
Q4 		$760K Buy
+3,230
New +$704K 0.81% 39

Other funds holding CLDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Marcus Capital's CLDX Position: Q3 2017 in Review

Marcus Capital sold out of Celldex Therapeutics (CLDX) in Q3 2017, closing a stake of 6,920 shares — an estimated $256K sold.

Marcus Capital first reported a position in CLDX in Q4 2015 and held it in 7 quarters. The position peaked at $760K in Q4 2015. 129 funds tracked by Wall St. Rank hold CLDX as of Q3 2017.

  • Marcus Capital reported no remaining Celldex Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Marcus Capital sold 6,920 Celldex Therapeutics shares in Q3 2017, an estimated $256K.
  • Marcus Capital first reported a position in Celldex Therapeutics in Q4 2015 and held it in 7 quarters.
  • Marcus Capital's Celldex Therapeutics position peaked at $760K in Q4 2015.
  • 129 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2017.

Based on Marcus Capital's 13F filing for Q3 2017, filed 7 Nov 2017.